Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
- Associated Therapies
- -
Lurasidone and Cognition in Bipolar I Disorder
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 53
- Registration Number
- NCT02147379
- Locations
- 🇨🇦
University of British Columbia, Department of Psychiatry, Vancouver, British Columbia, Canada
Lurasidone Pediatric Bipolar Study
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT02046369
- Locations
- 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
Lurasidone Pediatric Autism Study
- Conditions
- Autism
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01911442
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC, Maitland, Florida, United States
🇺🇸Institute for Behavioral Medicine, LLC, Smyrna, Georgia, United States
🇺🇸Capstone Clinical Research, Inc., Libertyville, Illinois, United States
Lurasidone Low-Dose - High-Dose Study Study
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT01821378
- Locations
- 🇺🇸
Center for Behavioral Health, LLC, Rockville, Maryland, United States
🇷🇴Spitalul Universitar de Urgenta Militar Central "Dr Carol Davila", Bucuresti, Romania
🇷🇴Spitalul Judetean de Urgenta "Sf. Pantelimon" Focsani, Focsani, Romania
Lurasidone Pediatric Pharmacokinetics Study
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01620060
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Woodland International Research Group, Inc., Little Rock, Arkansas, United States
🇺🇸Woodland Northwest Research, LLC, Springdale, Arkansas, United States
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT01575561
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, United States
🇵🇱NZOZ BioMed, Kielce, Poland
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 101
- Registration Number
- NCT01569659
- Locations
- 🇺🇸
Northwestern University Department of Psychiatry and Behavioral Sciences, Chicago, Illinois, United States
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 191
- Registration Number
- NCT01566162
- Locations
- 🇺🇸
AXIS Clinical Trials, Los Angeles, California, United States
🇺🇸CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 42
- Registration Number
- NCT01498770
Lurasidone Extended Use Study
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT01485640
- Locations
- 🇷🇴
Spitalul Clinic de Neuropsihiatrie Craiova, Craiova, Romania
🇨🇿Psychiatricka ambulance, Brno-mesto, Czech Republic
🇨🇿Vojenska nemocnice Olomouc, Olomouc, Czech Republic
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.